VISCHER advised Memo Therapeutics on the financing. Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF25 million series C financing round...
VISCHER advised Memo Therapeutics on the financing. Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF25 million series C financing round...
You must be a Standard 1 Year member to access this content.